0
Il n'y a pas de produit dans le panier !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Accueil > Siglec-6

Siglec-6

Brief Information

Name:Sialic acid-binding Ig-like lectin 6
Target Synonym:CD33 antigen-like 1,CDw327,Obesity-binding protein 1 (OB-BP1),OBBP1,CD33L,CD33L1,CD327
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:2
Lastest Research Phase:Phase 2 Clinical

Product ListCompare or Buy

Par statut du produit :
Par catégorie de produit :
Par espèce :
Par étiquette :
Par conjugaison :
Cat . Non Espèces Description du produit Structure Pureté Caractéristique
SI6-H5256 Human Human Siglec-6 / CD327 Protein, Fc Tag
SI6-H5256-structure
SI6-H5256-sds
ACRO Quality

Customer Reviews

Synonym Name

SIGLEC6,CD327,CD33L,CD33L1,OBBP1,OB-BP1,CDw327

Background

Sialic acid-binding Ig-like lectin 6 (SIGLEC6) is also known as CD antigen CD327, CD33 antigen-like 1 (CD33L or CD33L1), Obesity-binding protein 1 (OB-BP1). SIGLEC6 belongs to the immunoglobulin superfamily and SIGLEC (sialic acid binding Ig-like lectin) family, which contains two Ig-like C2-type (immunoglobulin-like) domains and one Ig-like V-type (immunoglobulin-like) domain. SIGLEC6 mediates sialic-acid dependent binding to cells. SIGLEC6 binds to alpha-2,6-linked sialic acid. The sialic acid recognition site may be masked by cis interactions with sialic acids on the same cell surface.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
anti-siglec-6 CAR-T cell therapy(Xuzhou Medical University) Phase 2 Clinical Xuzhou Medical University (Xzmu) Leukemia, Myeloid, Acute Details
AK-006 AK006 Phase 1 Clinical Allakos Inc Chronic Urticaria; Inflammation Details
anti-siglec-6 CAR-T cell therapy(Xuzhou Medical University) Phase 2 Clinical Xuzhou Medical University (Xzmu) Leukemia, Myeloid, Acute Details
AK-006 AK006 Phase 1 Clinical Allakos Inc Chronic Urticaria; Inflammation Details

This web search service is supported by Google Inc.

totop

Laisser un message